



**WENDEL**  
INVESTISSEMENT

Tuesday, June 1, 2004

## PRESS RELEASE

### **WENDEL Investissement Shareholders' Meeting Dividend: 1.05 euros per share Acquisition of Editis**

The Shareholders' Meeting of WENDEL Investissement held in Paris on June 1, 2004, and chaired by Ernest-Antoine Seillière, approved the financial statements for the year 2003, the dividend for that year and all of the proposed resolutions.

#### **1. Recent events**

In 2004, WENDEL has taken initiatives motivated by the Group's strategy to focus on unlisted assets.

- Agreement on the acquisition of Editis

The preliminary agreement with Lagardère on the acquisition of Editis for a corporate value of 660 million euros was presented to the Shareholders' Meeting. It was emphasized that in line with its strategy, WENDEL Investissement will provide Editis with the resources it needs for its long-term development so as to enable the company to regain leadership in the French and French-language markets.

- Sale of Trader Classified Media shares

WENDEL earned 322 million euros on the sale of Trader Classified Media shares in April 2004, generating non-recurring income of more than 140 million euros.

- Sale of Capgemini shares

In the first quarter, WENDEL Investissement sold 2.4 million Capgemini shares for 75 million euros and remains a shareholder of Capgemini with an equity interest of 2.4%.

#### **2. Share price**

Since the last Shareholders' Meeting, the share price increased by 62%. In May 2004, revalued net assets stood at 49 euros per share versus 39 euros per share in May 2003.

#### **3. Dividend: 1.05 euros per share**

Reflecting growth in the Group's 2003 results, a dividend of 1.05 euros per share was approved by the Shareholders' Meeting. With the tax credit (0.53 euro per share), this dividend offers a return of 6% on the average value of the stock in 2003. The dividend will be paid as of June 3, 2004.

#### **4. Prospects for 2004**

By combining their efforts to adapt and pursue their commercial investments, the Group's subsidiaries are on the right track and ready to benefit fully from the global recovery.

This document may not be distributed in the United States, the United Kingdom, Canada, Australia or Japan. This document does not constitute an offer to sell bioMérieux shares in the United States. BioMérieux shares may not be sold in the United States unless they have been registered or exempted from registration under the Securities Act of 1933, as modified. bioMérieux does not intend to register the offer mentioned in this document or a part of this offer in the United States nor to conduct a public sales offer for bioMérieux shares in the United States.

#### Contacts:

Christine Dutreil Tel.: +33 (0)1 42 85 63 24 / E-mail: [c.dutreil@wendel-investissement.com](mailto:c.dutreil@wendel-investissement.com)  
Gérard Lamy Tel.: +33 (0)1 42 85 63 75 / E-mail: [g.lamy@wendel-investissement.com](mailto:g.lamy@wendel-investissement.com)